Astellas Sales Up 1.1% Driven by Xtandi, OAB Drugs, despite Slump in Japan Business

Astellas Pharma’s sales increased 1.1% in April-September despite a drug price revision in April and generic inroads in Japan, the company said on October 31. In the first half of FY2018, the company posted group sales of 647 billion yen,...read more